Evgen Pharma PLC
LSE:EVG
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
|
Evgen Pharma PLC
LSE:EVG
|
3.4m GBP |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.3B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
174.4B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.3B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -195 650% |
| 30th Percentile | 0% |
| Median | 0.1% |
| 70th Percentile | 0.2% |
| Max | 4 630.7% |
Other Profitability Ratios
Evgen Pharma PLC
Glance View
Evgen Pharma Plc is a clinical stage drug development company, which engages in the development of pharmaceutical products and focus on cancer and neurological disease. The company is headquartered in Wilmslow, Cheshire and currently employs 8 full-time employees. The company went IPO on 2015-10-21. The firm is developing sulforaphane-based medicines focused on the treatment of cancer and inflammation. The firm's pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01 for the treatment of metastatic breast cancer and acute respiratory distress syndrome. The SFX-01 reduces the number of cancer stem cells in patient-derived breast cancer tissue in xenograft models. Its SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Evgen Pharma PLC is -518%, which is above its 3-year median of -836.4%.
Over the last 3 years, Evgen Pharma PLC’s Operating Margin has increased from -1 757.2% to -518%. During this period, it reached a low of -1 757.2% on Sep 30, 2020 and a high of -518% on Oct 30, 2023.